Junel Related Published Studies
Well-designed clinical trials related to Junel (Norethindrone / Estradiol)
Effect of the bile acid sequestrant colesevelam on the pharmacokinetics of pioglitazone, repaglinide, estrogen estradiol, norethindrone, levothyroxine, and glyburide. [2010.05]
Does hormone therapy improve age-related skin changes in postmenopausal women? A randomized, double-blind, double-dummy, placebo-controlled multicenter study assessing the effects of norethindrone acetate and ethinyl estradiol in the improvement of mild to moderate age-related skin changes in postmenopausal women. [2008.09]
Combined continuous ethinyl estradiol/norethindrone acetate does not improve forearm blood flow in postmenopausal women at risk for cardiovascular events: a pilot study. [2007.09]
Efficacy and safety of a new 24-day oral contraceptive regimen of norethindrone acetate 1 mg/ethinyl estradiol 20 micro g (Loestrin 24 Fe). [2007.01]
Impact of combined estradiol and norethindrone therapy on visuospatial working memory assessed by functional magnetic resonance imaging. [2006.11]
Escitalopram versus ethinyl estradiol and norethindrone acetate for symptomatic peri- and postmenopausal women: impact on depression, vasomotor symptoms, sleep, and quality of life. [2006.09]
Effects of low-dose norethindrone acetate plus ethinyl estradiol (0.5 mg/2.5 microg) in women with postmenopausal symptoms: updated analysis of three randomized, controlled trials. [2006.06]
Oral hormone therapy with 17beta-estradiol and 17beta-estradiol in combination with norethindrone acetate in the prevention of bone loss in early postmenopausal women: dose-dependent effects. [2005.11]
Effect of topiramate or carbamazepine on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in healthy obese and nonobese female subjects. [2003.04]
A randomized, double-blind, placebo-controlled, multicenter study that assessed the endometrial effects of norethindrone acetate plus ethinyl estradiol versus ethinyl estradiol alone. [2003.02]
Reduced vaginal bleeding in postmenopausal women who receive combined norethindrone acetate and low-dose ethinyl estradiol therapy versus combined conjugated equine estrogens and medroxyprogesterone acetate therapy. [2003.01]
The effect of food on the bioavailability of norethindrone and ethinyl estradiol from norethindrone acetate/ethinyl estradiol tablets intended for continuous hormone replacement therapy. [2003.01]
Effects of oral continuous and transdermal cyclic 17-beta estradiol and norethindrone acetate replacement therapy on platelet aggregation in postmenopausal women. [2002.08]
Randomized, double-masked, 2-year comparison of tibolone with 17beta-estradiol and norethindrone acetate in preventing postmenopausal bone loss. [2002.03]
Well-designed clinical trials possibly related to Junel (Norethindrone / Estradiol)
Effects of tibolone or continuous combined oestradiol/norethisterone acetate on
glucose and insulin metabolism. [2013]
Evaluation of a low-dose oral contraceptive pill for primary dysmenorrhea: a placebo-controlled, double-blind, randomized trial. [2011.05]
Randomized trial of leuprolide versus continuous oral contraceptives in the treatment of endometriosis-associated pelvic pain. [2011.04]
[Influence of estradiol administration mode on plasma insulin-like growth factor-I (IGF-I) and its binding proteins 1 and 3 concentration in postmenopausal women treated with norethisterone acetate]. [2011.03]
Evaluation of a low-dose oral contraceptive pill for primary dysmenorrhea: a
placebo-controlled, double-blind, randomized trial. [2011]
Physiological versus standard sex steroid replacement in young women with premature ovarian failure: effects on bone mass acquisition and turnover. [2010.12]
Estrogen plus progestin treatment: effect of different progestin components on serum markers of apoptosis in healthy postmenopausal women. [2010.11]
The effect of hormone therapy and tibolone on serum CD40L and ADAM-8 in healthy post-menopausal women. [2010.11]
Genistein aglycone: a new therapeutic approach to reduce endometrial hyperplasia. [2010.09]
Effect of abrupt discontinuation versus gradual dose reduction of postmenopausal hormone therapy on hot flushes. [2010.08]
Estrogen + progestin therapy and cognition: a randomized placebo-controlled double-blind study. [2010.08]
Effects of continuous combined hormone replacement therapy and clodronate on bone mineral density in osteoporotic postmenopausal women: a 5-year follow-up. [2010.08]
A randomized controlled trial of low-dose hormone therapy on myocardial ischemia in postmenopausal women with no obstructive coronary artery disease: results from the National Institutes of Health/National Heart, Lung, and Blood Institute-sponsored Women's Ischemia Syndrome Evaluation (WISE). [2010.06]
Short-term hormone treatment modulates emotion response circuitry in postmenopausal women. [2010.04]
Optimal tolerability of ultra-low-dose continuous combined 17beta-estradiol and norethisterone acetate: laboratory and safety results. [2010.02]
Effects of hormone therapy on depressive symptoms and cognitive functions in women with Alzheimer disease: a 12 month randomized, double-blind, placebo-controlled study of low-dose estradiol and norethisterone. [2010.01]
Genistein aglycone: a new therapeutic approach to reduce endometrial hyperplasia. [2010]
Effects of menopausal hormone therapy on hemostatic parameters, blood pressure, and body weight: open-label comparison of randomized treatment with estradiol plus drospirenone versus estradiol plus norethisterone acetate. [2009.12]
A randomized double-blind trial of the effects of hormone therapy on delayed verbal recall in older women. [2009.08]
Scheduled and unscheduled bleeding patterns with two combined hormonal contraceptives: application of new recommendations for standardization. [2009.08]
The effect of etoricoxib on the pharmacokinetics of oral contraceptives in healthy participants. [2009.07]
The decrease of soluble RAGE levels in rheumatoid arthritis patients following hormone replacement therapy is associated with increased bone mineral density and diminished bone/cartilage turnover: a randomized controlled trial. [2009.07]
Endometrium protection and acceptability of nasally administered continuously combined hormone therapy: a multicentre, multinational, double-blind trial in post-menopausal women evaluating three regimens of 17beta-estradiol and norethisterone when compared with an orally administered 17beta-estradiol norethisterone regimen. [2009.07]
Angeliq versus Activelle in normotensive postmenopausal women: a prospective, randomized pilot study. [2009.07]
Enhanced neuroactivation during verbal memory processing in postmenopausal women receiving short-term hormone therapy. [2009.07]
Association between efficacy and body weight or body mass index for two low-dose oral contraceptives. [2009.06]
A Canadian, multicentre study comparing the efficacy of a levonorgestrel-releasing intrauterine system to an oral contraceptive in women with idiopathic menorrhagia. [2009.04]
Improved bleeding profile and tolerability of tibolone versus transdermal E2/NETA treatment in postmenopausal women with female sexual dysfunction. [2009.04]
The effects of continuous combined oral estradiol and norethisterone on pulsatility index in internal carotid and uterine arteries in early postmenopausal Taiwanese women---a preliminary study. [2009.03]
Low-dose oral contraceptive pill for dysmenorrhea associated with endometriosis: a placebo-controlled, double-blind, randomized trial. [2008.11]
Estrogen and comprehension of metaphoric speech in women suffering from schizophrenia: results of a double-blind, placebo-controlled trial. [2008.11]
Effects of the route of estrogen administration on insulinlike growth factor-I, IGF binding protein-3, and insulin resistance in healthy postmenopausal women: results from a randomized, controlled study. [2008.11]
The effects of estrogen therapy and estrogen combined with different androgenic progestins on carbohydrate and lipid metabolism in overweight-obese younger postmenopausal women. [2008.06]
Differential impact of conventional and low-dose oral hormone therapy, tibolone and raloxifene on mammographic breast density, assessed by an automated quantitative method. [2008.05]
Testosterone and gonadotropins but not estrogen associated with spatial ability in women suffering from schizophrenia: a double-blind, placebo-controlled study. [2008.05]
Increased risk of recurrence after hormone replacement therapy in breast cancer survivors. [2008.04.02]
Effects of estradiol and norethisterone on lipids, insulin resistance and carotid flow. [2008.03.20]
Tibolone and transdermal E2/NETA for the treatment of female sexual dysfunction in naturally menopausal women: results of a randomized active-controlled trial. [2008.03]
Hemostatic markers in healthy postmenopausal women during intranasal and oral hormone therapy: a randomized trial. [2008.03]
Ultra-low-dose continuous combined estradiol and norethisterone acetate: improved bleeding profile in postmenopausal women. [2008.02]
Effects of continuous versus cyclical oral contraception: a randomized controlled trial. [2008.02]
Circulating leptin and ghrelin are differentially influenced by estrogen/progestin therapy and raloxifene. [2008.01.20]
A comparison of hormone therapies on the urinary excretion of prostacyclin and thromboxane A2. [2008]
Tibolone and low-dose continuous combined hormone treatment: vaginal bleeding pattern, efficacy and tolerability. [2007.12]
Effects of low-dose oral contraceptives on body weight: results of a randomized study of up to 13 cycles of use. [2007.11]
Effects of estrogen and estrogen-progestogen therapy on homocysteine levels and their correlation with carotid vascular resistance. [2007.11]
Low-dose continuous combinations of hormone therapy and biochemical surrogate markers for vascular tone and inflammation: transdermal versus oral application. [2007.11]
Effects of intranasal versus oral hormone therapy on asymmetric dimethylarginine in healthy postmenopausal women: a randomized study. [2007.11]
Effects on serum lipid and leptin levels of three different doses of norethisterone continuously combined with a fixed dose of 17beta-estradiol for nasal administration in postmenopausal women: a controlled, double-blind study. [2007.08]
Age moderates the short-term effects of transdermal 17beta-estradiol on endothelium-dependent vascular function in postmenopausal women. [2007.08]
Circulating chemoattractants RANTES, negatively related to endogenous androgens, and MCP-1 are differentially suppressed by hormone therapy and raloxifene. [2007.07]
Comparison of the effects of raloxifene and low-dose hormone replacement therapy on bone mineral density and bone turnover in the treatment of postmenopausal osteoporosis. [2007.07]
One-year endometrial safety evaluation of a continuous combined transdermal matrix patch delivering low-dose estradiol-norethisterone acetate in postmenopausal women. [2007.06.20]
Differential impact of conventional and low-dose oral hormone therapy (HT), tibolone and raloxifene on functionality of the activated protein C system. [2007.06]
Effects of standard and low dose 17beta-estradiol plus norethisterone acetate on body composition and leptin in postmenopausal women at risk of body mass index and waist girth related cardiovascular and metabolic disease. [2007.06]
Neutral effect of ultra-low-dose continuous combined estradiol and norethisterone acetate on mammographic breast density. [2007.06]
Testosterone addition during menopausal hormone therapy: effects on mammographic breast density. [2007.04]
Ultra-low-dose estradiol and norethisterone acetate: effective menopausal symptom relief. [2007.04]
Haemostatic activation in post-menopausal women taking low-dose hormone therapy: Less effect with transdermal administration? [2007.04]
Efficacy of citalopram on climacteric symptoms. [2007.03]
Testosterone inhibits estrogen/progestogen-induced breast cell proliferation in postmenopausal women. [2007.03]
Effects of postmenopausal hormone replacement therapy on body fat composition. [2007.02]
A comparison of the effects of sequential transdermal versus continuous orally administered hormone replacement therapies on plasma total homocysteine levels in postmenopausal women: a randomized, placebo-controlled study. [2007.02]
Effects of low-dose continuous combined hormone replacement therapy on glucose homeostasis and markers of cardiovascular risk in women with type 2 diabetes. [2007.01]
Early postmenopausal hormone therapy improves postural balance. [2007.01]
Effects of oral contraceptive, synthetic progestogen or natural estrogen pre-treatments on the hormonal profile and the antral follicle cohort before GnRH antagonist protocol. [2007.01]
Monophasic estrogen-progestogen therapy and sexuality in postmenopausal women. [2007]
Differential effects of conventional and low dose oral hormone therapy (HT), tibolone, and raloxifene on coagulation and fibrinolysis. [2007]
Effects of raloxifene and continuous combined hormone therapy on haemostasis variables: a multicenter, randomized, double-blind study. [2007]
Treatment of dysfunctional uterine bleeding in the perimenopause: the effects of adding combined estradiol/norethisterone acetate therapy to goserelin acetate treatment--a randomized, placebo-controlled, double-blind trial. [2006.12]
Pharmacokinetics of testosterone undecanoate injected alone or in combination with norethisterone enanthate in healthy men. [2006.11]
Conventional-dose hormone therapy (HT) and tibolone, but not low-dose HT and raloxifene, increase markers of activated coagulation. [2006.10.20]
Effects of estradiol alone and combined with norethisterone acetate on pulse-wave velocity in hypertensive postmenopausal women. [2006.10]
Endometrial safety, overall safety and tolerability of transdermal continuous combined hormone replacement therapy over 96 weeks: a randomized open-label study. [2006.10]
Oral medroxyprogesterone acetate and combination oral contraceptives for acute uterine bleeding: a randomized controlled trial. [2006.10]
Effects of low- or high-dose hormone therapy on fasting and post-methionine homocysteine levels in postmenopausal women. [2006.10]
Randomized trial of effects of continuous combined HRT on markers of lipids and coagulation in women with acute coronary syndromes: WHISP Pilot Study. [2006.09]
Tibolone and estradiol plus norethisterone acetate similarly influence endothelium-dependent vasodilatation in healthy postmenopausal women. [2006.08]
Effects of oral continuous 17beta-estradiol plus norethisterone acetate replacement therapy on abdominal subcutaneous fat, serum leptin levels and body composition. [2006.07]
The effect of various menopausal hormone therapies on markers of inflammation, coagulation, fibrinolysis, lipids, and lipoproteins in healthy postmenopausal women. [2006.07]
Effects of HRT on liver enzyme levels in women with type 2 diabetes: a randomized placebo-controlled trial. [2006.07]
Less effect of intranasal than oral hormone therapy on factors associated with venous thrombosis risk in healthy postmenopausal women. [2006.07]
Osteoporosis in primary biliary cirrhosis: a randomized trial of the efficacy and feasibility of estrogen/progestin. [2006.06]
The effect of low dose hormone therapy on mammographic breast density. [2006.04.20]
Intranasal continuous combined 17 beta-estradiol/norethisterone therapy improves the lipid profile in healthy postmenopausal women. [2006.04]
The effect of continuous combined HRT on glucose homeostasis and plasma lipids. A placebo-controlled study in postmenopausal women with type 2 diabetes. [2006.03.20]
Effects of dydrogesterone and norethisterone, in combination with oestradiol, on lipoproteins and inflammatory markers in postmenopausal women. [2006.03.20]
|
